Enzolytics, Inc. (OTCMKTS:ENZC) Short Interest Update

Enzolytics, Inc. (OTCMKTS:ENZC) saw a significant drop in short interest in the month of February. As of February 27th, there was short interest totaling 1,874 shares, a drop of 99.5% from the February 12th total of 412,513 shares. Based on an average daily volume of 16,015,665 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily volume of 16,015,665 shares, the days-to-cover ratio is presently 0.0 days.

Enzolytics Trading Down 20.0%

Shares of ENZC traded down $0.00 on Tuesday, hitting $0.00. The company’s stock had a trading volume of 13,544,150 shares, compared to its average volume of 6,403,851. Enzolytics has a fifty-two week low of $0.00 and a fifty-two week high of $0.00.

Enzolytics Company Profile

Enzolytics, Inc is a clinical-stage biotechnology company focused on advancing immunotherapeutic treatments for infectious diseases. Its core platform employs proprietary peptide and monoclonal antibody technologies designed to target and neutralize viral pathogens. The company’s lead candidate, Investigator Therapeutic Vaccine-1 (ITV-1), is a 72-amino-acid peptide engineered to bind multiple HIV-1 strains and support immune response in affected individuals.

In addition to its HIV program, Enzolytics has leveraged its antibody discovery engine to develop broadly neutralizing monoclonal antibodies against coronaviruses, including SARS-CoV-2.